PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

Journal for ImmunoTherapy of Cancer

Antoni Ribas¹  Leslie L Sharp⁴  Caius Radu⁵  Earl Avramis⁸  Encarnacion Montecino-Rodriguez³  Begoña Comin-Anduix⁵  Liu Wei⁶  Charles Ng⁷  Michelle Lee²  Mohammad Atefi⁷  Mark W Elliott²  Helena Escuin-Ordinas⁷ 

[1] Department of Medicine, Division of Hematology-Oncology, 11-934 Factor Building, Jonsson Comprehensive Cancer Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA;Pfizer Worldwide Research and Development, Oncology Research Unit, San Diego, CA, USA;Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, USA;Current address: Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Dr., San Diego, CA 92121, USA;Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, USA;Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, USA;Department of Medicine (Division of Hematology-Oncology) at David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, USA;Department of Surgery (Division of Surgical-Oncology), UCLA, Los Angeles, USA

关键词: Colon cancer;    PET imaging;    Immune activating antibodies;    CD137;    4-1BB;   

Others  :  814979
DOI  :  10.1186/2051-1426-1-14

 received in 2013-05-12, accepted in 2013-08-07,  发布年份 2013

【 摘 要 】

Background

Molecular imaging with positron emission tomography (PET) may allow the non-invasive study of the pharmacodynamic effects of agonistic monoclonal antibodies (mAb) to 4-1BB (CD137). 4-1BB is a member of the tumor necrosis factor family expressed on activated T cells and other immune cells, and activating 4-1BB antibodies are being tested for the treatment of patients with advanced cancers.

Methods

We studied the antitumor activity of 4-1BB mAb therapy using [¹⁸ F]-labeled fluoro-2-deoxy-2-D-glucose ([¹⁸ F]FDG) microPET scanning in a mouse model of colon cancer. Results of microPET imaging were correlated with morphological changes in tumors, draining lymph nodes as well as cell subset uptake of the metabolic PET tracer in vitro.

Results

The administration of 4-1BB mAb to Balb/c mice induced reproducible CT26 tumor regressions and improved survival; complete tumor shrinkage was achieved in the majority of mice. There was markedly increased [¹⁸ F]FDG signal at the tumor site and draining lymph nodes. In a metabolic probe in vitro uptake assay, there was an 8-fold increase in uptake of [³H]DDG in leukocytes extracted from tumors and draining lymph nodes of mice treated with 4-1BB mAb compared to untreated mice, supporting the in vivo PET data.

Conclusion

Increased uptake of [¹⁸ F]FDG by PET scans visualizes 4-1BB agonistic antibody-induced antitumor immune responses and can be used as a pharmacodynamic readout to guide the development of this class of antibodies in the clinic.

【 授权许可】

   
2013 Escuin-Ordinas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3(6):682-685.
• [2]Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007, 7(2):95-106.
• [3]Vinay DS, Kwon BS: Role of 4-1BB in immune responses. Semin Immunol 1998, 10(6):481-489.
• [4]Vinay DS, Kwon BS: Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11(5):1062-1070.
• [5]Wang C, Lin GH, McPherson AJ, Watts TH: Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009, 229(1):192-215.
• [6]Croft M: The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009, 9(4):271-285.
• [7]Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I, Dubrot J, Morales-Kastresana A, Perez-Gracia JL, Ochoa MC, et al.: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer research 2011, 71(3):801-811.
• [8]Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al.: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013, 123(3):1371-1381.
• [9]Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC, et al.: Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012, 61(10):1721-1733.
• [10]Massoud TF, Gambhir SS: Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003, 17(5):545-580.
• [11]Phelps ME, Schelbert HR, Mazziotta JC: Positron computed tomography for studies of myocardial and cerebral function. Ann Intern Med 1983, 98(3):339-359.
• [12]Singh AS, Radu CG, Ribas A: PET imaging of the immune system: immune monitoring at the whole body level. Q J Nucl Med Mol Imaging 2010, 54(3):281-290.
• [13]Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, et al.: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186(1):47-55.
• [14]Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-7420.
• [15]Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, Gambhir SS, Radu CG, Witte ON: Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci USA 2005, 102(48):17412-17417.
• [16]Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A: The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother 2010, 33(8):759-768.
• [17]Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH: Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 2003, 362(9388):945-950.
• [18]Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J: Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010, 51(3):340-346.
• [19]Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, et al.: Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3’-fluoro-3’-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci USA 2011, 108(45):18396-18399.
• [20]Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON: Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2’-deoxycytidine analog. Nat Med 2008, 14(7):783-788.